Genus (LON:GNS - Free Report) had its price target hoisted by Deutsche Bank Aktiengesellschaft from GBX 2,550 to GBX 2,900 in a report published on Monday, Marketbeat.com reports. They currently have a buy rating on the stock.
Separately, Shore Capital reissued a "buy" rating and set a GBX 2,900 price target on shares of Genus in a report on Thursday, September 4th. Two investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and an average target price of GBX 2,900.
View Our Latest Stock Report on GNS
Genus Price Performance
Shares of Genus stock traded down GBX 25 during trading on Monday, reaching GBX 2,450. 540,827 shares of the company's stock were exchanged, compared to its average volume of 256,822. The company has a debt-to-equity ratio of 53.12, a quick ratio of 1.08 and a current ratio of 1.80. Genus has a 1-year low of GBX 1,424 and a 1-year high of GBX 3,228.80. The company has a market cap of £1.61 billion, a P/E ratio of -39,516.13, a PEG ratio of 2.87 and a beta of 0.37. The firm's 50-day moving average price is GBX 2,538.66 and its 200 day moving average price is GBX 2,132.15.
Genus (LON:GNS - Get Free Report) last posted its quarterly earnings results on Thursday, September 4th. The company reported GBX 81.80 EPS for the quarter. Genus had a return on equity of 1.41% and a net margin of 1.18%. As a group, research analysts anticipate that Genus will post 70.9644323 earnings per share for the current year.
About Genus
(
Get Free Report)
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand.
See Also
Before you consider Genus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genus wasn't on the list.
While Genus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.